Progression-Free Survival: Does a Correlation With Survival Justify Its Role as a Surrogate Clinical Endpoint?

被引：4
作者：
Becker, Andreas [1 ,2 ]
Eichelberg, Christian [1 ]
Sun, Maxine [3 ]
机构：
[1] Univ Hosp Hamburg Eppendorf, Dept Urol, D-20246 Hamburg, Germany
[2] Prostate Canc Ctr, Martini Clin, Hamburg, Germany
[3] Univ Montreal, Ctr Hlth, Dept Urol, Canc Prognost & Hlth Outcomes Unit, Montreal, PQ, Canada
来源：
CANCER | 2014年 / 120卷 / 01期
关键词：
RENAL-CELL CARCINOMA; BLIND PHASE-III; INTERFERON-ALPHA; CANCER; BIOMARKERS; EVEROLIMUS; SORAFENIB; PREDICTOR; SUNITINIB; PAZOPANIB;
D O I：
10.1002/cncr.28378
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
In this editorial, the authors critically discuss the current role and limitations of progression-free survival as a surrogate endpoint of overall survival in clinical trials.
引用
收藏
页码：7 / 10
页数：4
相关论文
共 30 条
[1]   More clinical cancer treatments judged by progression-free rather than overall survival [J].
Beckman, Mary .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (14) :1068-1069
[2]   Progression-Free Survival: Meaningful or Simply Measurable? [J].
Booth, Christopher M. ;
Eisenhauer, Elizabeth A. .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (10) :1030-1033
[3]   Use of Meta-Analysis for the Validation of Surrogate Endpoints and Biomarkers in Cancer Trials [J].
Buyse, Marc .
CANCER JOURNAL, 2009, 15 (05) :421-425
[4]   Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial [J].
Escudier, Bernard ;
Pluzanska, Anna ;
Koralewski, Piotr ;
Ravaud, Alain ;
Bracarda, Sergio ;
Szczylik, Cezary ;
Chevreau, Christine ;
Filipek, Marek ;
Melichar, Bohuslav ;
Bajetta, Emilio ;
Gorbunova, Vera ;
Bay, Jacques-Olivier ;
Bodrogi, Istvan ;
Jagiello-Gruszfeld, Agnieszka ;
Moore, Nicola .
LANCET, 2007, 370 (9605) :2103-2111
[5]   Sorafenib in advanced clear-cell renal-cell carcinoma [J].
Escudier, Bernard ;
Eisen, Tim ;
Stadler, Walter M. ;
Szczylik, Cezary ;
Oudard, Stephane ;
Siebels, Michael ;
Negrier, Sylvie ;
Chevreau, Christine ;
Solska, Ewa ;
Desai, Apurva A. ;
Rolland, Frederic ;
Demkow, Tomasz ;
Hutson, Thomas E. ;
Gore, Martin ;
Freeman, Scott ;
Schwartz, Brian ;
Shan, Minghua ;
Simantov, Ronit ;
Bukowski, Ronald M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :125-134
[6]   Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival [J].
Escudier, Bernard ;
Bellmunt, Joaquim ;
Negrier, Sylvie ;
Bajetta, Emilio ;
Melichar, Bohuslav ;
Bracarda, Sergio ;
Ravaud, Alain ;
Golding, Sophie ;
Jethwa, Sangeeta ;
Sneller, Vesna .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) :2144-2150
[7]  
Halabi S, 2014, CANCER, V120, P52
[8]   Progression-Free Survival as a Predictor of Overall Survival in Men With Castrate-Resistant Prostate Cancer [J].
Halabi, Susan ;
Vogelzang, Nicholas J. ;
Ou, San-San ;
Owzar, Kouros ;
Archer, Laura ;
Small, Eric J. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (17) :2766-2771
[9]   Progression-Free Survival as a Predictor of Overall Survival in Metastatic Renal Cell Carcinoma Treated With Contemporary Targeted Therapy [J].
Heng, Daniel Y. C. ;
Xie, Wanling ;
Bjarnason, Georg A. ;
Vaishampayan, Ulka ;
Tan, Min-Han ;
Knox, Jennifer ;
Donskov, Frede ;
Wood, Lori ;
Kollmannsberger, Christian ;
Rini, Brian I. ;
Choueiri, Toni K. .
CANCER, 2011, 117 (12) :2637-2642
[10]   Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma [J].
Hudes, Gary ;
Carducci, Michael ;
Tomczak, Piotr ;
Dutcher, Janice ;
Figlin, Robert ;
Kapoor, Anil ;
Staroslawska, Elzbieta ;
Sosman, Jeffrey ;
McDermott, David ;
Bodrogi, Istvan ;
Kovacevic, Zoran ;
Lesovoy, Vladimir ;
Schmidt-Wolf, Ingo G. H. ;
Barbarash, Olga ;
Gokmen, Erhan ;
O'Toole, Timothy ;
Lustgarten, Stephanie ;
Moore, Laurence ;
Motzer, Robert J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (22) :2271-2281
123